KRYS
Krystal Biotech Inc.
Company Overview
| Mkt Cap | $5.74B | Price | $282.27 |
| Volume | 220.40K | Change | +1.09% |
| P/E Ratio | 64.4 | Open | $276.58 |
| Revenue | $290.5M | Prev Close | $279.24 |
| Net Income | $89.2M | 52W Range | $122.80 - $295.98 |
| Div Yield | N/A | Target | $284.60 |
| Overall | 57 | Value | 50 |
| Quality | 50 | Technical | 72 |
No chart data available
About Krystal Biotech Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Latest News
Krystal Biotech (KRYS) Gets a Buy from H.C. Wainwright
Analysts Are Bullish on Top Healthcare Stocks: Evolus (EOLS), Krystal Biotech (KRYS)
Krystal Biotech outlines rare disease growth strategy update
Krystal Biotech (KRYS) Receives a Rating Update from a Top Analyst
Bank of America Securities Sticks to Their Buy Rating for Krystal Biotech (KRYS)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KRYS | $282.27 | +1.1% | 220.40K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |